Table 1.
The distribution of PNI in different pathological types of esophageal cancer.
| Study | Country | Re. period | N | PNI+(%) | Male(%) | T stage(T1+T2/T3+T4) | N stage(N-/N+) | LVI+() | LNM+() | Outcome | Study quality |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EC | |||||||||||
| Alcan S, 2022 (10) | Turkey | 2008-2018 | 50 | 30(60%) | 33(66%) | 13/37 | 21/29 | - | - | OS | 7 |
| Yıldırım ÖA, 2022 (11) | Turkey | 2011-2021 | 64 | 10(15.6%) | 44(69%) | - | - | 15(23%) | - | - | 7 |
| Huang Z, 2022 (12) | China | 2019-2020 | 533 | 180(33.8%) | 433(81.2%) | 201/332 | 247/286 | 326(61.2%) | 286(53.7%) | - | 8 |
| Wang YP, 2020 (6) | China | 2012-2016 | 162 | 32(19.8%) | 127(79.5%) | 66/96 | 82/80 | - | - | OS DFS | 7 |
| Zheng CY, 2019 (13) | China | 2014-2016 | 182 | 120(65.9%) | 144(79.1%) | 112/70 | - | - | - | - | 6 |
| Velickovic D, 2019 (14) | Serbia | 2004-2016 | 409 | 135(33%) | 333(81.4%) | 86/316 | 80/325 | - | - | - | 7 |
| Zhang WY, 2018 (15) | China | 2006-2012 | 408 | 72(17.6%) | 357(87.5%) | 173/235 | 205/203 | - | - | - | 7 |
| Zeng YZ, 2018 (16) | China | 2014-2016 | 141 | 30(21.3%) | 56(39.7%) | 10/61 | - | - | - | - | 6 |
| Miao N, 2018 (17) | China | 2007-2014 | 250 | 47(18.8%) | 175(70%) | 115/115 | 165/85 | - | - | - | 7 |
| Faiz Z, 2018 (18) | Netherlands | 2000-2015 | 81 | 51(63%) | - | 0/81 | 22/59 | - | - | OS DFS | 7 |
| Zhu TY, 2017 (19) | China | 2012-2013 | 177 | 116(65.5%) | 150(84.7%) | 108/69 | - | - | 111(62.7%) | - | 7 |
| Gao X, 2017 (20) | China | 2008-2012 | 247 | 92(37.2%) | 149(60.3%) | - | - | - | 128(51.8%) | - | 6 |
| Li ZY, 2016 (21) | China | 2010-2015 | 1160 | 147(12.7%) | 830(71.6%) | 296/864 | 540/620 | - | - | OS | 7 |
| Sun YH, 2015 (7) | China | 1981-2011 | 26 | 5(19.2%) | 23(88.5%) | 10/16 | 16/10 | 7(26.9%) | - | OS DFS | 7 |
| Dong X, 2014 (22[] | China | 2007-2010 | 248 | 14(6%) | 184(74.2%) | 114/134 | - | 127(51.2%) | - | - | 7 |
| Tachezy M, 2014 (23) | Germany | 1992-2009 | 644 | 36(6%) | 517(80.3%) | 295/347 | 242/395 | 209(32.5%) | - | - | 7 |
| Dolan JP, 2013 (24) | USA | 1995-2011 | 146 | 85(58.2%) | 120(84.5%) | - | - | - | - | - | 6 |
| Noble F, 2013 (8) | UK | 2005-2010 | 246 | 34(13.8%) | 195(79.3%) | 104/118 | 128/118 | - | - | OS DFS | 7 |
| Gray RT, 2012 (25) | UK | 1999-2000 | 42 | 15(35.7%) | 35(83.3%) | 13/29 | 28/14 | 36(85.7%) | - | - | 7 |
| Fassan M, 2010 (26) | Italy | 2002-2006 | 111 | 37(33.3%) | 93(83.8%) | - | - | - | - | - | 6 |
| Izzo JG, 2006 (27) | USA | NR | 43 | 16(37.2) | 41(95%) | 5/38 | 11/32 | - | - | - | 7 |
| Khan OA, 2004 (28) | UK | 1987-2001 | 219 | 11(5%) | 145(66.2%) | - | - | - | - | - | 6 |
| Glickman JN, 1999 (29) | USA | 1985-1996 | 145 | 52(35.9%) | - | - | - | - | 67(46.2%) | - | 6 |
| Tanaka A, 1998 (30) | Japan | NR | 104 | 48(46.2%) | 84(80.8%) | 30/74 | 46/55 | 69(66.3%) | 55(52.9%) | - | 7 |
| ESCC | - | ||||||||||
| Cheng J, 2022 (31) | China | 2021-2022 | 149 | 15(10%) | 123(82.6%) | 5/144 | 10/139 | 8(5%) | - | - | 7 |
| Xie C, 2022 (32) | China | 2012-2018 | 195 | 42(21.5%) | 140(71.8%) | 72/122 | 91/104 | - | 91(46.7%) | - | 7 |
| Li A, 2021 (33) | China | 2015-2020 | 143 | 39(27.3%) | 85(59.4%) | - | - | - | - | - | 6 |
| Peng H, 2021 (34) | China | 2013-2017 | 121 | 12(10%) | 96(79.3%) | 55/66 | - | - | 58(47.9%) | OS | 7 |
| Yeh JC, 2021 (35) | China | 2009-2017 | 278 | 63(22.7%) | 251(90.3%) | 95/128 | 180/98 | 80(28.8%) | - | - | 8 |
| Zeng YZ, 2021 (36) | China | 2014-2016 | 97 | 10(10.3%) | 78(80.4%) | 17/80 | 41/56 | - | 56(57.7%) | DFS | 7 |
| Li QM, 2020 (37) | China | 2015-2019 | 443 | 58(13.1%) | 259(58.5%) | 277/166 | - | - | 117(26.4%) | - | 7 |
| Tian H, 2020 (38) | China | 2016-2018 | 150 | 35(23.3%) | 102(68%) | 70/80 | - | - | 60(40%) | - | 7 |
| Cui J, 2020 (39) | China | 2012-2018 | 407 | 210(51.6%) | 390(95.8%） | 114/293 | - | - | 232(57%) | - | 7 |
| Guo YN, 2020 (40) | China | 2009-2013 | 162 | 119(73.5%) | 108(66.7%) | 30/162 | - | - | - | - | 6 |
| Lee HK, 2020 (9) | Korea | 2000-2018 | 64 | 13(20.3%) | 60(93.8%) | 36/28 | 39/25 | - | - | OS DFS | 7 |
| Tang Y, 2019 (41) | China | 2010-2015 | 347 | 44(12.7%) | 267(76.9%) | - | - | - | - | - | 6 |
| Lin G, 2019 (42) | China | 2011-2017 | 101 | 86(85.1%) | 78(77.2%) | 50/50 | - | - | - | - | 7 |
| Rong L, 2019 (43) | China | 1999-2003 | 378 | 125(33.1%) | 307(81.2%) | 103/275 | 189/189 | - | - | OS DFS | 7 |
| Wang H, 2018 (44) | China | 2008-2014 | 117 | 30(25.6%) | 87(74.4%) | 60/57 | 75/42 | - | 43 (36.8%) | - | 7 |
| Hong ZP, 2018 (45) | China | 2014-2017 | 108 | 43(39.8%) | 106(98.1%) | 10/98 | - | - | 87(80.6%) | - | 7 |
| Tsai CY, 2017 (46) | China | 1998-2008 | 177 | 77(43.5) | 171 (96.6%) | 60/117 | 103/74 | 71 (40.1%) | - | - | 7 |
| Tu CC, 2017 (47) | China | 2009-2014 | 91 | 15(16.5%) | 88(96.7%) | 21/70 | 27/54 | 21(23.1%) | - | OS DFS | 7 |
| Wang H, 2017 (48) | China | 2010-2015 | 446 | 113(25.3%) | 310(69.5%) | 70/376 | 282/164 | - | 164(36.8%) | OS | 8 |
| Xu G, 2017 (49) | China | 2008-2011 | 302 | 153(50.7%) | 233(77.2%) | 146/156 | 165/137 | - | - | DFS | 7 |
| Hsieh CC, 2016 (50) | China | 2006-2013 | 81 | 24(29.6%) | 70(86.4%) | 24/57 | 31/50 | 36(44.4%) | - | OS DFS | 8 |
| Wu J, 2016 (51) | China | 2003-2010 | 1435 | 274(19.1%) | 1254(87.4%) | 430/1005 | 671/764 | - | - | OS | 7 |
| Sato-Kuwabara Y, 2016 (52) | Brazil | 1980-1999 | 95 | 27(28.4%) | 78(82.1%) | - | - | - | - | - | 6 |
| Ning ZH, 2015 (53) | China | 2005-2010 | 243 | 54(22.2%) | 194(79.8%) | 51/192 | 106/137 | - | - | OS DFS | 7 |
| Park SY, 2015 (54) | Korea | 2010-2014 | 85 | 5(6%) | 77(90.6%) | - | - | - | - | - | 6 |
| Chen JW, 2014 (55) | China | 2000-2007 | 433 | 209(48.3%) | 321(74.1%) | 124/309 | 233/200 | - | - | - | 8 |
| Szumilo J, 2009 (56) | Poland | 1995-2001 | 39 | 27(69.2%) | 36(92.3%) | 1/38 | 7/32 | - | - | - | 6 |
| Lee EJ, 2008 (57) | Korea | 1994-2001 | 251 | 14(6%) | 110(92%) | - | - | 7(3%) | - | - | 6 |
| Wang Y, 2004 (58) | China | 2000-2000 | 25 | 5(20%) | 19(76%) | 9/16 | 15/10 | - | - | - | 7 |
| Roh MS, 2004 (59) | Korea | 1996-2003 | 56 | 12(21.4%) | 51(91.1%) | 24/32 | - | 22(39.3%) | 27(48.2%) | - | 7 |
| Chaves P,1997 (60) | Portugal | 1986-1990 | 37 | 17(45.9%) | 31(83.8%) | 8/29 | - | - | - | - | 7 |
| Sarbia M, 1995 (61) | Germany | 1978-1992 | 161 | 42(26.1%) | 132(82%) | 42/119 | 64/97 | - | - | - | 6 |
| EAC | |||||||||||
| Merritt RE, 2020 (62) | USA | 2010-2018 | 215 | 44(20.5%) | 186(86.5%) | 55/163 | 85/130 | 53 (24.7%) | - | OS | 8 |
| Tapias L, 2020 (63) | USA | 2002-2017 | 196 | 104(53.1%) | 166(84.7%) | - | 61/135 | - | 135(68.9%) | OS | 7 |
| Turato C, 2019 (64) | Italy | NR | 75 | 35(46.7%) | 67(89.3%) | - | - | - | - | - | 6 |
| Dislich B, 2017 (65) | Switzerland | 1990-2011 | 112 | 46(41.1%) | - | 43/69 | - | - | 60(53.6%) | - | 7 |
| Drage MG, 2017 (66) | USA | 1989-2011 | 120 | 34(28.3%) | 97(80.8%) | - | - | 46 (38.3%) | - | - | 6 |
| Patel AK, 2016 (67) | USA | 1996-2015 | 73 | 29(39.7%) | 67(91.8%) | 21/37 | 32/38 | 14(19.2%) | - | - | 7 |
| Thies S, 2016 (68) |
Germany
Switzerland |
1996-2011 | 200 | 63(31.5%) | - | 88/112 | - | 107(53.5%) | 107(53.5%) | - | 7 |
| Singhi AD, 2015 (69) | USA | 1997-2009 | 205 | 94(45.9%) | 170(83%) | 60/145 | 26/179 | 158(77.1%) | - | OS | 8 |
| Castonguay MC, 2014 (70) | Canada | 1998-2005 | 103 | 57(55.3%) | 86(83.5%) | 38/65 | 35/68 | - | - | - | 6 |
| Mehta KS, 2014 (71) | USA | NR | 128 | 63(49.2%) | 95(74.2%) | - | - | - | - | - | 6 |
| Smith E, 2014 (72) | Australia | NR | 65 | 30(46.2%) | 56(86.2%) | 25/40 | 28/37 | - | - | OS | 7 |
| Lagorce C, 2003 (73) | France | 1976-1997 | 66 | 37(56.1%) | 63(95.5%) | - | - | - | - | - | 6 |
| Torres C, 1999 (74) | USA | 1987-1996 | 96 | 31(32.3%) | 83(86.5%) | 35/48 | - | - | 36(37.5%) | - | 6 |
LVI, lymphovascular invasion; LNM, Lymph node metastasis; NR, No reported.